Barinthus Biotherapeutics (STU:2AB) Net Loan


STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.56
GF Value €0.98
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Net Loan?

Net Loan only applies to banks and insurance companies.

STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.56 is trading 42.9% below its estimated GF Value™ of €0.98.

Key valuation signals for STU:2AB:

  • Net Loan:
  • GF Value™: €0.98 vs. price of €0.56 (42.9% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.56
Price
€0.98
GF Value